Coherus BioSciences Q4 Adj. EPS $(0.34), Inline, Sales $12.748M Miss $13.944M Estimate

Benzinga
03/10

Coherus BioSciences (NASDAQ:CHRS) reported quarterly losses of $(0.34) per share which met the analyst consensus estimate. This is unchanged from the same period last year. The company reported quarterly sales of $12.748 million which missed the analyst consensus estimate of $13.944 million by 8.58 percent. This is a 64.85 percent increase over sales of $7.733 million the same period last year.

免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10